Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) [Trend Analysis] regains street interests, as shares dropped -0.43% on Thursday and it traded at $99.56. The 52-week high of the share price is -36.56% and 52-week low of the share price is 91.46%. Former U.S. SEC attorney Willie Briscoe along with securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Anacor Pharmaceuticals, Inc. (ANAC) concerning the merger with Pfizer, Inc. Under the terms of the agreement, valued at approximately $5.2 billion, Anacor shareholders will only receive $99.25 in cash per share held.
The investigation centers on whether Anacor’s Board of Directors is acting in the shareholders’ best interests, whether the board is properly negotiating a higher share price for the shareholders, and whether the board has employed an adequate process to review and act on the proposed transaction. The Briscoe Law Firm, PLLC is a full service business litigation and shareholder rights advocacy firm with more than 20 years of experience in complex litigation and transactional matters.
Moving toward technical analysis, the current ratio, or the liquidity ratio of a company was calculated 6.30 as compared to its debt to equity ratio stands at 0. This is an important indicator as a higher ratio typically suggests that investors are investing more confidently as compared to companies in the same industry has lower ratios. When calculating in the EPS estimates for the current year from sell-side analysts, the Price to current year EPS stands at 32.40%. Investors looking further ahead will note that the Price to next year’s EPS is 67.90%.
Major bullish and bearish trends reflect in rating research, from pool of WSJ analyst gave 130 as a highest price target, medium point hits to 99.25, while the lowest share price targets assigned 95. The data compelled by Wall Street Journal average suggest average price target would by 105.88, where as current price stood at 99.56. Moderately analysts issue miscellaneous recommendation for ANAC, as 3 experts rated as “BUY” security, 1 analyst have faith on stocks as “Overweight,” moreover 2 experts rated as “Hold”.
As for as concerns shares volumes, in share capital Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) has 43.53 million outstanding shares among them 42.66 million shares have been floated in market exchange. The firm’s institutional ownership remained 86% while insider ownership included 0.90%.
The stock showed weekly upbeat performance of 51.88%, which maintained for the month at 64.67%. Likewise the positive performance for the quarter recorded as 41.74% and for the year was 58.99%, while the YTD performance remained at -11.87%.